Fosun Pharma To Participate In Consolidated Listing Of Small Pharmaceutical Firms
This article was originally published in PharmAsia News
Small- and mid-sized pharmaceutical enterprises in China are facing especially tough times due to bottlenecks such as brand building and fund shortages. A group of small and medium firms in Beijing has announced its intention last April to band together and negotiate to bring investments public. Fosun Pharma has expressed interest and is having preliminary contact with the companies. If successful, the partnership will become a new model for China's pharmaceutical development. However, industry analysts observe that establishing such a venture comes with major challenges like the evaluation of each party's assets and securing government support. To address these issues, Beijing Pharmaceutical Profession Association will hold a meeting with 10 Beijing pharmaceutical enterprises to discuss the collaboration. (Click here for more - Chinese Language)
You may also be interested in...
A WHO recommendation to explicitly exempt low-THC CBD from international narcotics controls has been emphatically rejected by UN member states. The CBD industry had hoped for a positive outcome to remove regulatory pressure on product manufacturers in Europe and around the world.
After its historic first emergency approval, analysts at Bernstein has upgraded predictions for Pfizer/BioNTech's COVID-19 vaccine in 2021 and beyond.
How UK and EU device regulations will differ in 2021, UK approved bodies and Northern Ireland's unfettered access to the UK market were key themes at the ABHI’s annual regulatory conference.